Subtype
Malignant Cerebellar Neoplasm
CI-CAN-00008976Explore in graph →
62 active trials7 evidence items
- NCIt
- C3569
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00008976Explore in graph →
Clinical trials
207 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (28)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06193759 | Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)(IMPACT) | recruiting | Phase 1 | 12 | Children's National Research InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT00085735 | Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma | completed | Phase 3 | 549 | Children's Oncology GroupNETWORK | 7 | Jun 9, 2026 |
| clinicaltrials |
| NCT00392327 | Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET | completed | Phase 3 | 379 | Children's Oncology GroupNETWORK | 5 | Jun 8, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02875314 | HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors | active not recruiting | Phase 4 | 250 | Parth PatelOTHER | 3 | Jun 3, 2026 | clinicaltrials |
| NCT04978727 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 35 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT07589361 | Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors(VBS-CSI-PT-PED) | not yet recruiting | — | 38 | Ruijin HospitalOTHER | 0 | May 15, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03583528 | DOTATOC PET/CT for Imaging NET Patients | active not recruiting | — | 800 | British Columbia Cancer AgencyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05128903 | Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study | active not recruiting | Phase 2 | 22 | St. Jude Children's Research HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors | terminated | — | 57 | Pediatric Brain Tumor ConsortiumNETWORK | 2 | Apr 23, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07516353 | my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults | not yet recruiting | N/A | 143 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03581240 | An Intermediate Expanded Use Trial of DFMO | available | — | — | Giselle ShollerOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03361033 | Components of Social Functioning in Survivors of Pediatric Brain Tumors | completed | — | 80 | St. Jude Children's Research HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT00336024 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma | completed | Phase 3 | 91 | Children's Oncology GroupNETWORK | 4 | Jan 23, 2026 | clinicaltrials |
| NCT05106296 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | recruiting | Phase 1 | 37 | Theodore S. JohnsonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04049669 | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | active not recruiting | Phase 2 | 130 | Theodore S. JohnsonOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07291102 | Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma | not yet recruiting | Phase 3 | 96 | Nationwide Children's HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03500991 | HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | active not recruiting | Phase 1 | 10 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT06898684 | Medulloblastoma Online Video-based Exercise Pilot Study(MOVE) | recruiting | N/A | 15 | Aron OnerupOTHER_GOV | 2 | Dec 16, 2025 | clinicaltrials |
| NCT02238899 | Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma | completed | — | 354 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04081701 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.(DOMINO-START) | recruiting | Phase 4 | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT01878617 | A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | active not recruiting | Phase 2 | 660 | St. Jude Children's Research HospitalOTHER | 4 | Nov 13, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT03904862 | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery | terminated | Phase 1 / Phase 2 | 21 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT04402073 | Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma(PersoMed-I) | terminated | Phase 2 | 20 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Oct 23, 2025 | clinicaltrials |
| NCT01351870 | Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma (PNET4)(SIOP-PNET-4) | completed | Phase 3 | 52 | Institut CurieOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01063114 | Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma | completed | N/A | 90 | Massachusetts General HospitalOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT03893487 | Fimepinostat in Treating Brain Tumors in Children and Young Adults(PNOC016) | active not recruiting | Early Phase 1 | 30 | Sabine Mueller, MD, PhDOTHER | 2 | Jul 11, 2025 | clinicaltrials |
| NCT06779487 | Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline(BIO-RIN) | recruiting | — | 200 | Tata Memorial CentreOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04474964 | Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.(FOR-WNT2) | recruiting | N/A | 30 | Tata Memorial CentreOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06323408 | Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas(BZKF-AYA) | not yet recruiting | — | 72 | University Hospital RegensburgOTHER | 0 | Mar 25, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04315064 | Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma | completed | Early Phase 1 | 2 | The University of Texas Health Science Center, HoustonOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04023669 | Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | completed | Phase 1 | 21 | St. Jude Children's Research HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06814353 | Intraoperatively Observed Site of Origin and Growth Pattern of Medulloblastoma(ISOP) | enrolling by invitation | — | 100 | Christian DorferOTHER | 3 | Feb 7, 2025 | clinicaltrials |
| NCT05298995 | GD2-CAR T Cells for Pediatric Brain Tumours | recruiting | Phase 1 | 54 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 26, 2024 | clinicaltrials |
| NCT04501718 | Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children | recruiting | Phase 2 | 44 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials